Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

New England Journal of Medicine

Volumn 362, Issue 24, 2010, Pages 2260-2270

  Kantarjian, Hagop ^a   Shah, Neil P ^b   Hochhaus, Andreas ^c   Cortes, Jorge ^a   Shah, Sandip ^d   Ayala, Manuel ^e   Moiraghi, Beatriz ^f   Shen, Zhixiang ^g   Mayer, Jiri ^h   Pasquini, Ricardo ⁱ   Nakamae, Hirohisa ^j   Huguet, Françoise ^k   Boqué, Concepción ^l   Chuah, Charles ^m   Bleickardt, Eric ⁿ   Bradley Garelik, M Brigid ⁿ   Zhu, Chao ⁿ   Szatrowski, Ted ⁿ   Shapiro, David ⁿ   Baccarani, Michele ^o  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d Hemato Oncology Clinic   (India)

^e HOSPITAL DE ESPECIALIDADES   (Mexico)

^f HOSPITAL RAMOS MEJÍA   (Argentina)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁱ Hospital de Clinicas de Curitiba   (Brazil)

^j OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k CHU PURPAN   (France)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m SINGAPORE GENERAL HOSPITAL   (Singapore)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; CORTICOSTEROID; DASATINIB; DIURETIC AGENT; HYDROXYUREA; IMATINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL CRISIS; BLEEDING; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MUSCULOSKELETAL PAIN; MYALGIA; MYOSITIS; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUPERFICIAL EDEMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADOLESCENT; COMPARATIVE STUDY; DISEASE COURSE; DRUG ANTAGONISM; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MYELOID LEUKEMIA; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLAST CRISIS; DISEASE PROGRESSION; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; YOUNG ADULT;

EID: 77953725855     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1002315     Document Type: Article

References (34)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
3. Gleevec (imatinib mesylate) tablets: prescribing information. Rev. ed. East Hanover, NJ: Novartis Pharmaceuticals, November 2007.
4. The chronic myelogenous leukemia clinical practice guidelines in oncology, version 1. Washington, DC: National Comprehensive Cancer Network, 2009.
5. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
6. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
7. Sprycel (dasatinib): prescribing information. Rev. ed. New York: Bristol-Myers Squibb, November 2007.
8. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6.
9. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12.
10. Shah NP, Kim D-W, Kantarjian HM, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40.
11. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
12. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63.
13. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
14. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315-21.
15. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-84.
16. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:462. abstract.
17. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
18. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445-51.
19. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404.
20. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
21. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-9.
22. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. Clin Cancer Res 2006;12:7374-9.
23. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
24. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8. (Pubitemid 28280552)
25. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
26. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
27. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-86.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. Prognostic factors. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, eds. Chronic myeloid leukemia: biology and treatment. London: Martin Dunitz, 2001:205-23.
29. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
30. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010. DOI: 10.1056/NEJMoa0912614.
31. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
32. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037-42.
33. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-6.
34. Paschka P, Müller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha: low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-94.